The goal is clear - sustainable health through informed choices and continuous support! Explore our latest blog, "Decoding GLP-1 Tapering: A Strategic Approach to Sustainable Health," by Kristin Baier MD, VP of Clinical Development, where she delves into the nuances of GLP-1 tapering, a precise approach designed to sustain metabolic health and obesity treatment. Key Highlights Include: - Who Benefits? Understand the criteria for tapering and the collaborative decision-making process between clinicians and members. - Potential Outcomes: Learn about dosage adjustments and the potential transition to other medications. - Evidence-Based: Backed by the latest research and expert opinions, our approach integrates medication with lifestyle modifications for lasting health benefits. Read the full article for a deeper dive into GLP-1 tapering strategies and their clinical implications. https://lnkd.in/e2VDSpRB #HealthcareInnovation #ClinicalExcellence #GLP1 #MetabolicHealth #ObesityTreatment
Calibrate’s Post
More Relevant Posts
-
Commercial Sales Executive @ WW | Health, Wellness and Benefits Leadership | Business Development |Employer Benefit Consultant
When it comes to determining whether to cover GLP-1 drugs for the treatment of obesity, each organization is in a different position. It is imperative to include both cost-control and cost-saving opportunities when computing ROI and assessing outcomes.
Every organization is in a different place when it comes to making decisions about covering GLP-1 medications for treating obesity. When calculating the ROI and evaluating results, it’s important to look at both cost-control and cost-saving opportunities. “The real ROI of GLP-1 medications” white paper can help guide you on how to invest and optimize budgets while supporting your employees’ health. Download now https://bit.ly/4ay3X7G Rich Gamret, FSA, MAAA
To view or add a comment, sign in
-
-
Every organization is in a different place when it comes to making decisions about covering GLP-1 medications for treating obesity. When calculating the ROI and evaluating results, it’s important to look at both cost-control and cost-saving opportunities. “The real ROI of GLP-1 medications” white paper can help guide you on how to invest and optimize budgets while supporting your employees’ health. Download now https://bit.ly/4ay3X7G Rich Gamret, FSA, MAAA
To view or add a comment, sign in
-
-
This World Hypertension Day, we're highlighting three projects that showcase our commitment to improving the management of high blood pressure across the lifespan. From supporting new mothers with hypertensive pregnancies through digital tools (SNAP2), to helping older adults safely reduce their blood pressure medications (OPTIMISE 2), our researchers are developing innovative solutions to this widespread health challenge. We're also evaluating the real-world effectiveness of a digital self-monitoring program (SHIP) that empowers patients to take control of their blood pressure. Central to all of our research is a focus on patient and public involvement. By partnering with patients, we ensure that our work remains relevant, sensitive to lived experiences, and ultimately more impactful. This collaborative approach has the potential to inform updated clinical guidelines, targeted interventions, and wider implementation of digital health tools. Read more at: https://lnkd.in/eHhMD76c #WorldHypertensionDay #hypertension #digitalhealth #patientengagement
To view or add a comment, sign in
-
#HCP: Research shows that holistic care can lead to better health outcomes for people with cardio-renal-metabolic (C-R-M) conditions, like diabetes and heart failure. Dr. Janani Rangaswami, Nephrologist and Professor of Medicine at George Washington University, provides practical tips to implement a guideline-directed, multidisciplinary approach to C-R-M health management. Learn more: https://bit.ly/3PvtYdh #KidneyWk
To view or add a comment, sign in
-
Really enjoyed this well written piece. Totally agree we need large multi-center RCTs on lifestyle and behavioral interventions. But these programs and services are not reimbursed nor priced like medications so innovation at scale will not be easy. Secondly, there is push for discussion/rethinking of the value of lifestyle and behavioral change only in so much as they can prove to augment/optimize obesity medications. But the value of behavioral change goes well beyond weight loss and my concern is that reductive conversations will only push our practice of medicine more so towards a prescribe and forget culture. It's time to shift from a 'prescribe and forget' mindset to one that values comprehensive care. #HealthInnovation #LifestyleMedicine #ObesityCare #EPILifestyle24
We enjoyed this piece by Francis Finucane and Enda Murphy. The way we evaluate lifestyle interventions in clinical trials needs a closer look for us to truly understand their impact. Moreover, the power of personalized treatment strategies is undeniable—they can significantly uplift patient outcomes. As healthcare pioneers, let's embrace these insights and we can drive forward-looking changes in obesity management that not only elevate patient care but also set new benchmarks in treatment efficacy. https://lnkd.in/dPcg8eXE #semaglutide #obesity #lifestyle #healthinnovation #wegovy #ozempic
To view or add a comment, sign in
-
-
We are pleased to share an obesity taxonomy EASO recently developed using a Delphi process. This taxonomy is important for patients and health practitioners across Europe and will assist policy-makers in better understanding and discussing obesity. 🗣 Why Words Matter 🗣 Accurate framing and consistent terminology are vital for: -Ensuring accurate diagnosis -Effective treatment -Consistent research -Clear communication -Informed policy-making -Improved patient outcomes Read more here: https://lnkd.in/eyPfvpVK
To view or add a comment, sign in
-
-
Let's dive into something groundbreaking: Tirzepatide, previously lauded for its weight loss and glucose control benefits, now shows promise in reducing blood pressure among those with obesity, according to the SURMOUNT-1 trial findings. Seeing blood pressure reductions up to 10.6 mmHg, Tirzepatide steps up as a potential multifaceted treatment strategy. This isn't just about a new drug; it's about reimagining patient care with more holistic, integrated treatment approaches. Are we ready to embrace this shift towards more comprehensive health management? #Hypertension #Obesity #Tirzepatide
To view or add a comment, sign in
-
-
We’re still in the early days of the GLP-1 revolution, but it’s already changing how patients and caregivers think about and treat obesity. WeightWatchers’ Dr. Spencer Nadolsky explains. Read more in What the Future: Wellness. https://lnkd.in/ggCrKtSq Be sure to also join us for our deep dive webinar on April 9 https://lnkd.in/g4bDVxwe
To view or add a comment, sign in
-
-
We’re still in the early days of the GLP-1 revolution, but it’s already changing how patients and caregivers think about and treat obesity. WeightWatchers’ Dr. Spencer Nadolsky explains. Read more in What the Future: Wellness. https://lnkd.in/gDfBEAYz Be sure to also join us for our deep dive webinar on April 9 https://lnkd.in/g6qD2qDY
To view or add a comment, sign in
-
-
Explore the results! The OBSERVE study evaluated the attitudes of healthcare professionals and patients in the US toward obesity and therapeutic options to treat it. Visit https://e.lilly/4cZ4FMn to learn more. #obesity #obesitymedicine #obesityresearch
To view or add a comment, sign in
-
Business Development @Fullscript | Artist by Trade | Always Keeping Things Creative
1moPersonalized healthcare for the win! It's all about finding that sweet spot with meds and lifestyle habits for long-term health wins. 🌟